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Abstract
Introduction The androgen receptor (AR) is the master
regulator of prostate cancer cell metabolism. Degarelix is a
novel gonadotrophin-releasing hormone blocker, used to
decrease serum androgen levels in order to treat advanced
human prostate cancer. Little is known of the rapid meta-
bolic response of the human prostate cancer tissue samples
to the decreased androgen levels.
Objectives To investigate the metabolic responses in
benign and cancerous tissue samples from patients after
treatment with Degarelix by using HRMAS 1H NMR
spectroscopy.
Methods Using non-destructive HR-MAS 1H NMR spec-
troscopy we analysed the metabolic changes induced by
decreased AR signalling in human prostate cancer tissue
samples. Absolute concentrations of themetabolites alanine,
lactate, glutamine, glutamate, citrate, choline compounds
[t-choline = choline ? phosphocholine (PC) ? glycerophos-
phocholine (GPC)], creatine compounds [t-creatine = cre-
atine (Cr) ? phosphocreatine (PCr)], taurine, myo-inositol
and polyamines were measured in benign prostate tissue
samples (n = 10), in prostate cancer specimens from
untreated patients (n = 7) and prostate cancer specimens
from patients treated with Degarelix (n = 6).
Results Lactate, alanine and t-choline concentrations were
significantly elevated in high-grade prostate cancer sam-
ples when compared to benign samples in untreated
patients. Decreased androgen levels resulted in significant
decreases of lactate and t-choline concentrations in human
prostate cancer biopsies.
Conclusions The reduced concentrations of lactate and
t-choline metabolites due to Degarelix could in principle be
monitored by in vivo 1H MRS, which suggests that it
would be possible to monitor the effects of physical or
chemical castration in patients by that non-invasive
method.
Keywords Prostate  Cancer  Metabolomics  Degarelix 
Metabolism  NMR  HR-MAS
1 Introduction
Prostate cancer is the second commonest cause of cancer
death in males in the UK (Thompson et al. 2007). Nuclear
magnetic resonance (NMR) spectroscopy methods have
been used, both in vivo and ex vivo, to differentiate
between benign prostate hypertrophy (BPH) and malignant
prostate cancer samples (Fowler et al. 1992). A unique
metabolic trait of the prostate gland is abnormal citrate
metabolism: normal prostate accumulates high citrate
concentrations and secretes it into the seminal fluid
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(Costello et al. 1999). This metabolic trait is lost in prostate
cancer. In addition, the multiply-coupled methylene pro-
tons of three polyamines (putrescine, spermidine (a dimer
of putrescine) and spermine (a dimer of spermidine)
overlap; this results in broad 1H NMR resonances between
the choline and creatine signals that are detectable by NMR
in the normal prostate and are reduced in cancer. Liu et al.
found increased gene expression and activity of ornithine
decarboxylase (ODC), a rate limiting enzyme in the poly-
amine biosynthesis pathway that synthesizes putrescine
from ornithine, in benign prostatic hyperplasia samples
(Liu et al. 2000). Spermine, a polyamine that is found to be
reduced in prostate cancer tissue samples when measured
by high-resolution magic angle spinning (HRMAS) 1H
NMR, showed a linear correlation with the volume per-
centage of normal epithelial cells that were quantified by
histopathology methods (Cheng et al. 2001). Additionally,
1H NMR spectroscopic studies on malignantly transformed
human prostatic cells often show increased choline com-
pounds, suggesting altered membrane phospholipid meta-
bolism (Ellen Ackerstaff et al. 2001). Importantly, Santos
et al. (2010) have shown that HRMAS can be performed on
human tissue without losing transcriptomic data. They
concluded that despite a decrease in RNA integrity number
(RIN) following HRMAS spectroscopy, analysis of
expression microarrays demonstrated no significant change
in gene expressions between HRMAS-analysed and control
samples of surgical and biopsy tissues.
1H NMR measurements of citrate from human seminal
fluid and expressed prostatic fluid have been shown to
outperform serum PSA in identifying prostate cancer
(Kline et al. 2006), and citrate, myo-inositol and spermine
have also been shown to be potential age-independent
biomarkers of prostate cancer in human expressed pro-
static secretions (Serkova et al. 2008). Tessem et al.
investigated the use of lactate and alanine as metabolic
biomarkers of prostate cancer by using HRMAS 1H NMR
spectroscopy on biopsy samples (Tessem et al. 2008). An
analysis of the metabolite profiles of human prostate tissue
extracts, obtained from HR-NMR spectroscopy concluded
that citrate and spermine decreased whereas lactate and
choline increased in prostate cancer samples (Kumar et al.
2014). In another recent study, HR-NMR data analysis of
serum samples from prostate cancer patients and healthy
controls established that the biomarkers alanine, pyruvate
and glycine distinguished 90 % of cancer cases (84.4 %
sensitivity and 92.9 % specificity) and also discriminated
92.9 % of low grade cases (92.5 % sensitivity and 93.3 %
specificity) (Kumar et al. 2015). All these above-men-
tioned studies were aimed at establishing magnetic reso-
nance methods either to distinguish normal prostate from
benign (and also from malignant) neoplastic tissue or to
follow the metabolic changes in comparison with the
progression of indices of malignancy and/or aggressive-
ness (factors such as cellularity and Gleason grade) of the
prostate cancer. These studies have quantified the
metabolites either in relation to an internal standard like
trimethylsilyl propanoic acid (TSP) (Swanson et al.
2008, 2006) or by using the external electronic signal
reference method known as electronic reference to access
in vivo concentrations (ERETIC) (Albers et al. 2009). The
use of relative metabolite concentrations or metabolite
ratios may lead to ambiguous results if the supposedly
constant metabolite in the ratio actually changes, so sev-
eral methods have recently been proposed for obtaining
absolute concentrations (Albers et al. 2009; Ratiney et al.
2010). LCModel, which has been widely used for esti-
mating metabolite concentrations from in vivo 1H MRS
data of brain, has also been used on HRMAS 1H NMR
data from human brain tumours tissue samples (Piccirillo
et al. 2012) and prostate cancer biopsies (Garcia-Martin
et al. 2011; Madhu et al. 2014; DiCamillo et al. 2005). We
have developed a modified LC-model basis set in order to
get absolute concentrations of metabolites from human
prostate biopsies.
Androgen deprivation therapy (ADT) is the standard
clinical approach to the management of advanced prostate
cancer; nowadays drugs are used to lower the serum
androgen levels (this was historically achieved by surgical
removal of the testes) resulting in clinical remission in
95 % of cases (Bruchovsky et al. 2006). A recent phase III
trial concluded that Degarelix (a novel gonadotropin-re-
leasing hormone antagonist) achieved rapid suppression of
PSA levels and castrate testosterone levels irrespective of
baseline levels in prostate cancer patients (Damber et al.
2012). In another study, Degarelix showed a rapid reduc-
tion of testosterone levels in prostate cancer patients, with
95 % of patients having castrate levels of serum testos-
terone 28 days after administration (Klotz et al. 2008). A
recent study showed that Degarelix inhibits prostate cell
growth in normal, hyperplastic and cancer cell lines, pos-
sibly by involvement of a cell-cycle related mechanism,
leading to apoptosis (Sakai et al. 2015) and another recent
study has evaluated the effects of Degarelix treatment on
human prostate cancer by immunohistochemistry and
transcript profiling (Shaw et al. 2015). However there is no
data available showing how the metabolism of human
prostate tissue is affected by Degarelix treatment. In the
present study, the HRMAS 1H NMR spectroscopic method
was used to analyse surgically resected human benign and
prostate cancer samples with and without Degarelix treat-
ment (tissue removed surgically 7 days after administration
of Degarelix from patients with confirmed castrate levels of
serum testosterone) in order to evaluate the metabolic
changes associated with medical castration. To the best of
our knowledge this is the first study to investigate
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metabolic changes due to Degarelix treatment in prostate
cancer tissue samples.
2 Materials and methods
2.1 Clinical Sample collection
Full ethical approval was obtained for all elements of the
study including clinical sample collection and analysis:
NCT01852864 for Degarelix-treated patients (REC ref:
11/H0311/2) and NCT00967889 for untreated patients
(REC ref: 01/4/061).
The study was designed to examine the early effects of
chemical castration (by Degarelix administration) on
human prostate cancer. Patients were recruited to the study
through the urology outpatient clinic at Cambridge
University NHS Trust, Cambridge, UK. Six patients with
high-risk prostate cancer (PSA[ 20 ng/ml or Gleason
grade[ 7 or clinical stage C cT2c) were administered
240 mg of Degarelix S.C. (donated by Ferring Pharma-
ceuticals) in Addenbrooke’s Clinical Research Facility,
7 days before undergoing radical prostatectomy.
These patients were matched for known risk factors
(age, serum PSA, tumour grade and stage) with ten patients
who underwent radical prostatectomy without neoadjuvant
Degarelix. For all patients the prostate was sampled and
samples snap frozen as described (Warren et al. 2013). We
took care to minimise the time that the tissue samples were
left at room temperature as the exposure of surgical sam-
ples to room temperature can increase the lactate levels.
Samples obtained from patients who had not received
Degarelix are referred to as untreated. Prostate samples
found to contain cancer are called untreated cancer; pros-
tate samples where no cancer was found are called
untreated benign. For patients administered Degarelix,
serum samples were taken immediately before adminis-
tration of Degarelix and immediately prior to surgery for
measuring pre- and post-Degarelix treatment testosterone
levels respectively. Serum testosterone levels at the time of
surgery were confirmed as castrate for all patients treated
7 days previously with Degarelix (data not shown). See
Table 1 for patient and tumour characteristics.
Tissue cores were obtained using a published method
(Warren et al. 2013). Slices from each end of the cores
were stained with H&E and examined by a specialist
uropathologist (AW), and the presence or absence of
tumour was confirmed. Untreated means the patients had
not been exposed to presurgical Degarelix. Twenty-three
post-surgical prostate samples were snap frozen in cryo-
genic vials (in liquid nitrogen), and preserved at -80 C
until the NMR analysis. Ten prostates were sampled from
patients who had not been exposed to Degarelix. Samples
containing cancer were isolated from seven of these pros-
tates, (untreated cancer) and samples which did not contain
prostate cancer (untreated benign) were obtained from all
ten of the prostates. Samples containing prostate cancer
were obtained from the prostates of six patients who had
been treated with Degarelix (treated cancer).
One tissue sample was analysed at a time by transferring it
on dry ice from the -80 C freezer to a Category 2 con-
tainment cabinet. The sample was cut to size on the dry ice so
as to fit into the 4 mm plastic Bruker HRMAS rotor insert.
The sample weight was determined by weighing the insert
before and after loading with the sample (weights for sam-
ples; benign prostate = 14.63 ± 1.55 mg, untreated can-
cer = 8.13 ± 0.58 mg, Degarelix-treated cancer = 7.18 ±
1.55 mg). A small screw was fitted onto the top of the insert
and the whole capped insert was inserted into the Bruker
4 mm HRMAS NMR zirconium rotor. The top screw of the
rotor was fitted and the rotor was placed into the NMR
spectrometer.
2.2 Metabolite data acquisition
HRMAS 1H NMR data acquisition was performed on a
Bruker 600 MHz instrument with a 4 mm HRMAS probe.
All the spectra were obtained using TOPSPIN 2.5 Bruker
software and at a spin rate of 3000 Hz and a sample tem-
perature of 4 C. A water-suppressed pulse sequence with a
repetition time of 8 s, 128 transients and 64 K time domain
points was used to get the metabolite spectrum. The cor-
responding water spectrum was acquired with 8 s repetition
time, eight transients and 64 K time domain points. A
water-suppressed CPMG pulse sequence with acquisition
parameters of 8 s repetition time, 128 transients and 64 K
time domain points was used with a T2 filter (T2 filter times
with 50 ms, 100 ms and 200 ms) to acquire metabolite
spectra with suppression of the broad lipid and macro-
molecule signals. The total data acquisition time for each
sample was about 1 h 30 min.
2.3 Data analysis
2.3.1 Multivariate analysis
We analysed the metabolite profiles from prostate tissue
samples by using the pattern recognitions methods princi-
pal component analysis (PCA) and orthogonal projections
to latent structures-discriminant analysis (OPLS-DA). The
spectra were binned from 0.5 to 4.5 ppm with 0.01 ppm
intervals. Binned data were exported to SIMCA (Umet-
rics) software for multivariate analysis. All the bins were
mean-centred and scaled (with Pareto scaling) and PCA
analysis was conducted to find out the general trends and
outliers in the data, while OPLS-DA was used to get a clear
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discrimination between the groups. Scores plots were used
for classification of the samples and loadings plots to
identify the metabolites responsible for the separation of
samples in the scores plots.
2.3.2 Metabolite quantitation
LCModel software (http://www.s-provencher.com/pages/
lcmodel.shtml) was used on water-suppressed spectra to
estimate the metabolite concentration (Provencher 1993).
A modified LCModel basis set was used. Since these were
not brain tumours, NAA and NAAG were omitted from the
analysis; instead, citrate, polyamines and phosphocreatine
(PCr) signals were simulated. Crammer–Rao lower bound
values (standard deviation of 20 %) in LCModel were used
to estimate reliable fittings of metabolites from NMR
spectra. The absolute metabolite concentrations were
quantified relative to the water signal observed in each
individual experiment (Madhu et al. 2014; Madhu et al.
2006; Piccirillo et al. 2012) and then Student’s t test (two
tailed) was carried out. The methodology for estimation of
metabolite concentrations was validated with phantoms
containing known concentrations of metabolites. The dye
used in the process of punching the biopsy gets mixed with
the tissue sample and it produces a single peak at about
3.70 ppm in the HRMAS 1H NMR spectrum. We also
simulated this signal so as to get an optimum residual
between the observed and fitted spectrum in the LCModel
fittings. Supplementary Table 1s shows the metabolites
with their ChEBI identifiers and abbreviations used in this
study.
3 Results
Table 1 shows the characteristics of the patients included
in this study and their prostate cancers. Median age, biopsy
grade, pathological stage and nodal status of the samples
were not significantly different between untreated (control)
and Degarelix-treated groups. Histology has been the ‘‘gold
standard’’ for evaluating cellular malignancy in routine
clinical diagnosis for prostate cancer and Fig. 1 clearly
shows the cellular differences between human benign
prostate and both untreated and treated prostate cancer
tissues. Degarelix-treated histological sections show a
degree of hormonal change, with more vacuolation and
apoptosis compared to the untreated prostate cancer
samples.
Figure 2 shows the observed HRMAS 1H NMR spectra
(in black) from benign, untreated cancer and Degarelix-
treated human prostate tissue samples; the LCModel fitted
spectrum line appears in red. The residuals, the difference
between the observed (black) and fitted spectrum (red)
appear on the top of the plots, showing that these spectral
Table 1 Baseline characteristics of degarelix-treated and untreated cohorts
Degarelix-treated cancer (n = 6) Untreated cancer (n = 7) Untreated benign (n = 10)
Age (years) [median(range)] 60.52 (47–68) 60.42 (51–67) 61.43 (51–68)
PSA (ng/ml) [median(range)] 8.59 (5.5–12.2) 10.32 (5.8–18) 11.51 (5.2–13.9)
Clinical stage 1 1 2 2
2 2 3 7
3 3 2 1
Biopsy Gleason score 6 1 1 1
7 3 5 7
8 1 0 1
9 0 1 1
10 1 0 0
Pathological stage at prostatectomy 2 1 3 3
3 5 4 7
Prostatectomy Gleason score* 7 4 6 8
8 0 0 1
9 2 1 1
Nodal status negative 4 6 0
positive 2 1 1
* Post-prostatectomy Gleason score must be interpreted with caution as prostate cancer architecture and therefore Gleason score is affected by
hormonal therapy, even if short-lived. Mild architectural changes were observed in the post-treatment group. No patients had received any
hormonal treatment with a 5-alpha reductase inhibitor other than Degarelix within 6 months prior to undergoing radical prostatectomy
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fittings were optimal. The metabolite concentrations esti-
mated from LCModel fittings to HRMAS 1H NMR spectra
of human prostate samples are presented in Table 2.
The PCA scores plots showed a trend of separation of
untreated and Degarelix treated prostate cancer samples, as
can be seen in Fig. 3 (top panel), but it could not com-
pletely separate the two groups. We therefore performed
OPLS-DA (Fig. 3 bottom panel) in an attempt to obtain a
complete discrimination. The scores plot of OPLS-DA
(Fig. 3 bottom left panel) shows a clear separation of the
untreated and treated groups (though one sample from each
group overlaps). Information about the chemical shifts can
be obtained from the OPLS-DA loadings plot (Fig. 3 bot-
tom right panel) which shows that the bins containing
signals from metabolites such as choline-containing com-
pounds, lactate, glutamine, glutamate and myo-inositol are
causing the separation of two groups that had been
observed in the OPLS-DA scores plot.
Figure 4 shows that lactate and t-choline [choline ?
phosphocholine (PC) ? glycerophosphocholine (GPC)]
concentrations were significantly higher in the prostate
cancer samples compared to benign samples. The t-creatine
[creatine (Cr) ? phosphocreatine (PCr)] levels did not
show any significant differences in cancer samples com-
pared to benign samples (Fig. 4; Table 2). Citrate signals
could not be found in four out of seven cancer samples.
Lactate and t-choline concentrations in Degarelix-treated
cancer samples were significantly lower than in untreated
samples, while citrate and t-creatine levels did not show
any significant differences (Table 2). Though there was a
general tendency towards lower levels of alanine, choline,
glutamate, taurine and myo-inositol in prostate samples
from Degarelix-treated patients, the differences were not
statistically significant (Table 2). In general the ranges and
quartiles of the Degarelix treated samples were smaller
compared to both benign and untreated prostate cancer
samples (Table 2; Fig. 4; supplementary Fig. 1s).
In contrast, the benign tissue did not show any signifi-
cant changes following Degarelix treatment in any of the
metabolites estimated in this study (data not shown). Many
previous studies that are reviewed in the introduction and
discussion sections used metabolite ratios as markers to
discriminate the normal from the malignant samples, and
such data have been shown to be correlated with Gleason
grade (van Asten et al. 2008). In this study, however, we
found that metabolite ratios such as t-choline/t-creatine,
t-choline/citrate, (t-choline ? t-creatine)/citrate and (t-
choline ?t-creatine ? polyamines)/citrate were not dif-
ferent between the Degarelix-treated and untreated prostate
cancer samples (supplementary figure S2).
4 Discussion
Histopathological examination is the gold standard for
differentiating benign from cancerous prostate tissue in
clinical practice. In vivo and ex vivo NMR methods have
also been used to successfully distinguish the metabolic
differences between normal, benign and malignant tissues,
and these studies have generated new insights into treat-
ment-induced remodelling of metabolism of the tumour
Fig. 1 H&E sections from the patient prostate tissue samples
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Untreated Benign prostate tissue
Untreated prostate cancer













Fig. 2 LC Model fittings of water suppressed HRMAS 1H NMR
spectra from prostate tissue samples. Residuals between the observed
and fitted spectrum are also shown on each of the spectra. (Gln
glutamine Glu-Glutamate, Cit citrate, Cr creatine, PCr phosphocre-
atine, Cho choline, PC phosphocholine, GPC glycerophosphocholine,
Tau taurine, myo-Ino myo-Inositol)
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tissues. However, there is a paucity of data regarding the
metabolic effects of androgen deprivation on human
prostate cancer. We have used samples from a clinical
study of Degarelix to track the rapid metabolic changes
taking place in response to androgen deprivation. HRMAS
1H NMR represents a unique non-destructive method by
which to evaluate the metabolic changes to follow the anti-
cancer treatment.
4.1 Comparison of benign and tumour metabolites
The elevated lactate and alanine levels observed in tumour
samples compared to benign samples indicate enhanced
glycolysis (Fig. 4; Table 2). These samples showed the
well-known metabolic phenotype called the ‘‘Warburg
effect’’, which has been found in many cancer cells and
malignant tumour tissues (DeBerardinis et al. 2008; War-
burg et al. 1927; Ward and Thompson 2012). However, one
has to be careful with interpretation of lactate concentra-
tions in the ex vivo tissue samples as the exposure of
surgical samples to the room temperature can increase the
lactate levels.
Increased levels of choline and choline-containing
compounds have frequently been observed in cancer, by
both in vivo and by ex vivo MRS studies on cancer biop-
sies and cell extracts (Bertilsson et al. 2011, 2012;
Table 2 Estimated concentrations (in mM) of metabolites, lipids and macromolecules obtained from LCModel fittings of HRMAS 1H NMR
spectra of prostate samples
Metabolites Untreated-benign prostate
tissue
Untreated prostate cancer tissue Degarelix treated prostate cancer tissue
mean ± SEM mean ± SEM mean ± SEM
Alanine 1.13 ± 0.24 2.48 ± 0.18 2.09 ± 0.23
Acetate 3.04 ± 1.07 5.32 ± 1.58 3.19 ± 1.13
Choline (Cho) 1.62 ± 0.40 2.95 ± 0.73 1.43 ± 0.32
Creatine (Cr) 1.73 ± 0.29 1.59 ± 0.35 2.02 ± 0.43
Glutamine (Glu) 7.43 ± 2.74 13.90 ± 5.61 3.79 ± 1.66
Glutamate (Gln) 5.51 ± 1.32 11.20 ± 3.06 5.12 ± 0.72
Glycine 1.25 ± 0.18 1.56 ± 0.00 1.95 ± 0.27
PCh ? GPC 1.74 ± 0.21 3.32 ± 0.66 2.81 ± 0.28
Myo-inositol 9.17 ± 1.84 10.75 ± 2.10 7.79 ± 1.04
Lactate 15.59 ± 1.90 23.31 ± 2.54 15.21 ± 1.89
Lysine 4.44 ± 1.68 8.32 ± 3.25 2.20 ± 0.52
Phosphoethanolamine (PE) 15.38 ± 6.44 32.70 ± 13.35 8.99 ± 5.35
Scyllo-Inositol 2.34 ± 0.86 3.94 ± 1.37 1.34 ± 0.32
Taurine 6.40 ± 1.19 7.76 ± 1.29 6.02 ± 0.43
Phospho-Creatine (PCr) 1.63 ± 0.48 2.15 ± 0.81 1.05 ± 0.07
Citrate 5.82 ± 2.00 2.20 ± 1.05 3.05 ± 0.63
t-choline (Cho ? GPC ? PCh) 3.14 ± 0.38 5.66 ± 0.68 3.48 ± 0.51
t-creatine (Cr ? PCr) 2.59 ± 0.36 3.06 ± 0.52 2.15 ± 0.32
Glu ? Gln 12.66 ± 3.91 24.59 ± 8.31 8.62 ± 1.34
Lipids and macromolecules (MM)
Lipid 0.9 ppm 28.92 ± 3.93 31.48 ± 7.61 16.10 ± 4.34
MM 0.9 ppm 66.48 ± 0.00 10.56 ± 0.00 13.61 ± 1.51
Lipid 2.0 ppm 164.55 ± 101.44 206.02 ± 101.84 21.11 ± 12.04
MM 2.0 ppm 72.99 ± 18.43 114.85 ± 40.39 59.05 ± 22.04
Lip 1.5 ppm 1420.01 ± 229.64 1781.03 ± 682.35 544.69 ± 367.80
MM 1.4 ppm 5.50 ± 1.88 9.98 ± 2.03 9.84 ± 4.19
MM 1.7 ppm 243.13 ± 129.43 226.36 ± 165.19 60.00 ± 35.75
Polyamines 162.53 ± 65.74 191.87 ± 87.74 50.96 ± 9.56
Lipid 1.3 ppm 42.70 ± 6.77 55.42 ± 13.08 33.10 ± 8.77
SEM standard error mean, PCh phosphocholine, GPC glycerophosphocholine
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Giskeødega˚rd et al. 2013; Selnaes et al. 2013). Similarly,
the t-choline and (PC ? GPC) contents observed the
prostate cancer samples were significantly higher than in
benign prostate.
The higher glutamine and glutamate levels in cancer
biopsies compared to untreated benign prostate tissue
samples might be due to increased glutaminolysis
(DeBerardinis et al. 2007). The citrate levels in normal
Fig. 3 Results from Principal Component Analysis (top left and right panels) and OPLS-DA (bottom left and right panels). Green dots on the
left panels are samples from untreated patients (C) and blue dots are samples from Degarelix-treated patients (T)
Fig. 4 Lactate, t-choline and t-creatine metabolite changes in benign, untreated and Degarelix-treated prostate cancer
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prostate were found to be in the range of 5 mM–13 mM
depending on central or peripheral zone of prostate tissue,
whereas the citrate concentration in prostate cancer tissue
was about 1–3 mM (Costello et al. 1999; Costello et al.
2002). In the case of malignant prostate tissue citrate val-
ues can be less than 0.5 mM (Costello et al. 1999). We
could not observe citrate signals in four out of seven
prostate cancer tissue samples. Our estimated citrate levels
in normal and prostate cancer tissue samples (Table 2) are
in the same range as these above mentioned literature
values.
4.2 Degarelix effect on tumour metabolites
Reduced lactate levels in Degarelix-treated prostate can-
cer might be an indication of lower glycolysis (Table 2;
Fig. 4). Alanine, another product of glycolysis, showed a
similar trend but it did not reach statistical significance
(Table 2). A small increase of citrate levels was found in
Degarelix-treated prostate cancer compared to untreated
cancer samples, but it was not statistically significant
(Table 2). Total choline levels were significantly reduced
after Degarelix treatment (Table 2; Fig. 4). These lower
t-choline levels indicate that Degarelix has an effect on
membrane phospholipid metabolism. In a recent study
choline kinase alpha (CHKA) expression was decreased
in tissues from patients treated with Degarelix, both at the
transcript and protein levels, compared with control
patients without androgen deprivation (Asim et al. 2016).
Gene expression data from these samples (Shaw et al.
2015) shows a general trend of decrease of expression of
protein encoding genes along the major metabolic path-
ways. Degarelix treatment did not change the glutamine
and glutamate levels significantly (Table 2; supplemen-
tary Fig. 1). In general, the plots of metabolite concen-
trations show that the levels of metabolites in the samples
from the patients treated with Degarelix have smaller
ranges compared to samples from untreated patients. The
fact that even a study of this size, where very small
numbers of samples are involved, could find significant
changes in the lactate and t-choline metabolite concen-
trations shows the potential of using HRMAS 1H NMR
spectroscopy as a method to study the metabolic effects
of androgen deprivation therapy. Moreover these
metabolites can be readily observed on clinical MRI
scanners (even at 1.5T field strength), which makes them
potential biomarkers for following androgen deprivation
therapy by non-invasive in vivo 1H MRS. In clinical
applications, observation of the lactate signal might
require spectral editing, since some of the lipid signals
observed by in vivo 1H MRS of human prostate overlap
with lactate.
4.3 Could the effects of castration be reflected
in metabolite ratios?
HRMAS 1H NMR data from the prostate are sometimes
expressed as metabolite ratios with respect to citrate (Kobus
et al. 2015). The concentrations of spermine, citrate and the
ratio CCP/C [(total choline ? creatine ? polyamines)/ci-
trate] obtained from HRMAS 1H NMR of human prostate
tissues samples data using the peak assignment and quan-
tification program LCModel (Linear Combination Model)
showed that the cancer tissues could be distinguished from
normal tissue with a sensitivity of 86.9 % and specificity of
85.2 %. (Giskeødega˚rd et al. 2013). Metabolite ratios esti-
mated from the HRMAS 1H NMR data of human prostate
needle biopsies have shown a positive correlation of choline/
creatine (also t-choline/creatine) with Gleason score while a
negative correlation was observed for citrate/creatine with
Gleason score (van Asten et al. 2008). These ratios are not
always reliable indicators of progression or response, as
citrate levels are very low or even undetectable by NMR in
prostate cancer tissue samples. The metabolite ratio of
[(PC) ? (GPC)]/creatine has been found to be correlated
with the proportion of cancerous tissue in human prostate
samples (Stenman et al. 2011). In our study, metabolite
ratios normalised to t-creatine levels did not change signif-
icantly after Degarelix treatment whereas the absolute con-
centration of t-choline was significantly lower. Even though
membrane blebbing is a well-known feature of apoptosis the
choline levels do not change markedly, whereas creatine
levels decrease, possibly due to the cellular disintegration
process (Madhu et al. 2006). In this present study the failure
of the t-choline/t-creatine ratio to change significantly may
have been due to a simultaneous decrease in both metabolite
concentrations (Madhu et al. 2006) since the absolute con-
centrations show significant differences. Thus metabolite
ratios estimated through MR methods may not be reliable
indicators for following removal of testosterone in prostate
cancer.
5 Conclusions
Absolute concentrations of alanine, lactate, glutamine,
glutamate, citrate, t-choline, t-creatine, taurine, myo-inos-
itol and polyamine metabolites were measured in samples
of benign and (untreated and Degarelix treated) prostate
cancer tissue from patients. Lactate, alanine, t-choline and
(PC ? GPC) concentrations were significantly elevated in
high-grade prostate cancer tissue when compared to benign
prostate tissue samples. Degarelix treatment resulted in
significant decreases of lactate and t-choline concentrations
in the prostate cancer samples.
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Lactate and t-choline metabolite signals from the pros-
tate gland in humans can be monitored non-invasively by
in vivo 1H MRS on standard clinical MRI scanners. The
reduced concentrations of lactate and t-choline due to
Degarelix treatment that have been observed in this study
indicate that there is a potential application of in vivo 1H
MRS for monitoring androgen deprivation therapy non-
invasively during human prostate cancer treatment. It may
also be possible in the future to use MRS to localise
prostate cancer clones that are resistant to the metabolic
effects of androgen deprivation and subject them to tar-
geted treatment.
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